Role of Kinase Inhibitors in Treatment of Lymphoid Malignancies

Osmond JD’Cruz1 and Fatih M Uckun1,2,*

1Developmental Therapeutics Program, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles (CHLA), Los Angeles, USA
2Division of Hematology-Oncology, Department of Pediatrics, USA
3Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine (USC KSOM), Los Angeles, USA

Deregulation or upregulated expression of specific oncogenic kinases has been implicated in the pathobiology of B-lineage lymphoid malignancies [1-4]. The intracellular signaling cascades that are active in maintaining the malignant phenotypes in B-lineage leukemias and lymphomas involve multiple potential therapeutic targets such as SYK, BTK, PI3K/AKT/mTOR, Src, Ras/Raf/MEK/ERK, JAK/STAT, and Aurora kinases. Inhibiting these kinases and their signaling pathways may result in significant clinical benefit especially for patients with relapsed or refractory B-lineage lymphoid malignancies.

Several kinase inhibitors (e.g. R788, PCI-32765, ASP3026, GS-1101, MK-2206, CCI-779, LY317615, SB1518, and MLN8237) have demonstrated promising activity in the treatment of aggressive and chemotherapy resistant B-lineage leukemias and lymphomas. The robust antitumor activity and tolerability of newer kinase inhibitors documented in multiple clinical trials suggest that kinase inhibitor therapy could be effective in selected malignancies and might be successfully combined with other drugs for optimal efficacy against relapsed or refractory lymphomas. Clinical success of targeting kinases will be dependent on the identification of reliable molecular and clinical biomarkers associated with response. Further insights into the signaling pathways should stimulate the identification of novel agents against specific oncogenic kinases and facilitate the development of new therapeutics selectively inhibiting these molecular targets.

Acknowledgment

The project described was supported in part by DHHS grants U01-CA-151837, R01CA 154471 and R21-CA-164098 (F.M.U) from the National Cancer Institute. This work was also supported in part by 2011 V-Foundation Translational Research Award, Nautica Triathlon and its producer Michael Epstein, Ronald McDonald House Charities of Southern California, Couples against Leukemia Foundation and a William Lawrence & Blanche Hughes Foundation grant and 2012 Saban Research Institute Merit Award to F.M.U.

References


*Corresponding author: Fatih M. Uckun, Children’s Hospital Los Angeles, MS#160, Los Angeles, California 90027-0367, USA, E-mail: uckun@usc.edu

Received February 20, 2013; Accepted February 22, 2013; Published February 25, 2013

Citation: JD’Cruz O, Uckun FM (2013) Role of Kinase Inhibitors in Treatment of Lymphoid Malignancies. Transl Med 3: e117. doi:10.4172/2161-1025.1000e117

Copyright: © 2013 JD’Cruz O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.